← Leaderboards
Shridar Ganesan
Rutgers Biomedical And Health Sciences
$8,375,704
Attributed
$12,346,484
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,346,484 · 11
By mechanism
R01$8,576,488 · 4
P01$1,877,217 · 1
K01$754,650 · 1
P30$677,592 · 3
P50$253,470 · 1
R43$207,067 · 1
Top collaborators
- Anant Madabhushi6 shared
- Michael D Feldman5 shared
- Edmund C. Lattime4 shared
- Eileen White4 shared
- Hannah Gilmore1 shared
- Dave Harding1 shared
Most similar at Rutgers Biomedical And Health Sciences
Same institution · by research overlap
- Edmund C. Lattime$9,980,995
- Eileen White$14,897,334
- Nur Zeinomar$599,688
- Kyle Kristopher Payne$468,373
- Elaheh Hosseini$48,759
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMutationCellsSpecimenMolecularResponseGenomicsTumorDefectPhenotypeMemberPlayPathway InteractionsDna RepairBrca1 GeneResistanceTargeted TreatmentBaseClinical TrialsMutantResearch PersonnelTissuesMalignant Breast NeoplasmSignal Transduction
Grant awards (40)
Project 3: Chromatin modifiers of BRCA-related DNA repair Pathways$372,396
P01 · FY2025 · CA · contact PI
Clinical Investigation and Precision Therapy$269,566
P30 · FY2025 · CA · contact PI
Project 3: Chromatin modifiers of BRCA-related DNA repair Pathways$357,516
P01 · FY2024 · CA · contact PI
Clinical Investigation and Precision Therapy$9,429
P30 · FY2024 · CA · contact PI
Impact of mutation burden on cancer growth and the immune landscape$635,557
R01 · FY2023 · CA · contact PI
Evolution and clinical impact of clonal hematopoiesis of indeterminate potential in breast tumor microenvironment$630,053
R01 · FY2023 · CA · contact PI
Project 3: Chromatin modifiers of BRCA-related DNA repair Pathways$386,956
P01 · FY2023 · CA · contact PI
Comprehensive Genomics$88,228
P30 · FY2023 · CA · contact PI
Clinical Investigations and Precision Therapeutics$70,137
P30 · FY2023 · CA · contact PI
Evolution and clinical impact of clonal hematopoiesis of indeterminate potential in breast tumor microenvironment$642,911
R01 · FY2022 · CA · contact PI
Impact of mutation burden on cancer growth and the immune landscape$633,201
R01 · FY2022 · CA · contact PI
Project 3: Chromatin modifiers of BRCA-related DNA repair Pathways$388,234
P01 · FY2022 · CA · contact PI
Comprehensive Genomics$37,936
P30 · FY2022 · CA · contact PI
Clinical Investigations and Precision Therapeutics$19,847
P30 · FY2022 · CA · contact PI
Impact of mutation burden on cancer growth and the immune landscape$644,404
R01 · FY2021 · CA · contact PI
Project 3: Chromatin modifiers of BRCA-related DNA repair Pathways$372,115
P01 · FY2021 · CA · contact PI
Comprehensive Genomics$56,760
P30 · FY2021 · CA · contact PI
Clinical Investigations and Precision Therapeutics$29,658
P30 · FY2021 · CA · contact PI
Impact of mutation burden on cancer growth and the immune landscape$644,401
R01 · FY2020 · CA · contact PI
Computerized histologic image predictor of cancer outcome$598,709
R01 · FY2020 · CA
Comprehensive Genomics$56,745
P30 · FY2020 · CA · contact PI
Computerized histologic image predictor of cancer outcome$585,112
R01 · FY2019 · CA
Comprehensive Genomics$39,286
P30 · FY2019 · CA · contact PI
Computerized histologic image predictor of cancer outcome$608,223
R01 · FY2018 · CA
Computerized histologic image predictor of cancer outcome$624,988
R01 · FY2017 · CA
Computerized histologic image predictor of cancer outcome$699,670
R01 · FY2016 · CA
53BP1-Mediated Regulation of DNA Repair and Chemoresistance$329,260
R01 · FY2016 · CA · contact PI
53BP1-Mediated Regulation of DNA Repair and Chemoresistance$329,260
R01 · FY2015 · CA · contact PI
53BP1-Mediated Regulation of DNA Repair and Chemoresistance$319,383
R01 · FY2014 · CA · contact PI
53BP1-Mediated Regulation of DNA Repair and Chemoresistance$309,504
R01 · FY2013 · CA · contact PI
53BP1-Mediated Regulation of DNA Repair and Chemoresistance$341,852
R01 · FY2012 · CA · contact PI
Decision Support System for Predicting outcome of ER+ breast cancers$207,067
R43 · FY2011 · EB
BRCA1 AND X CHROMOSOME INACTIVATION$155,250
K01 · FY2008 · CA · contact PI
BRCA1 AND X CHROMOSOME INACTIVATION$155,250
K01 · FY2007 · CA · contact PI
P-1: Biology and Treatment of BRCA1-Associated and Sporadic Basal-like Cancers$109,836
P50 · FY2007 · CA · contact PI
BRCA1 AND X CHROMOSOME INACTIVATION$155,250
K01 · FY2006 · CA · contact PI
P-1: Biology and Treatment of BRCA1-Associated and Sporadic Basal-like Cancers$71,856
P50 · FY2006 · CA · contact PI
BRCA1 AND X CHROMOSOME INACTIVATION$155,250
K01 · FY2005 · CA
P-1: Biology and Treatment of BRCA1-Associated and Sporadic Basal-like Cancers$71,778
P50 · FY2005 · CA
BRCA1 AND X CHROMOSOME INACTIVATION$133,650
K01 · FY2004 · CA